MedX Health Corp. Provides Update on the Release of Its First Quarter 2020 Interim Financial Statements and Related Disclosures, and Retirement of a Director
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) provides an update on the filing of its Interim Financial Statements and related Disclosures for the First Quarter of fiscal 2020 (the "Interim Disclosures") which was delayed owing to COVID-19 related issues. As previously announced in its Press Release dated May 27, 2020, the Company anticipates that the Interim Disclosures will be filed by July 13, 2020.
MedX Announces Executive Changes
MedX Health Corp. ("MedX") (MDX - TSXV), announced today that President and CEO Scott Spearn has resigned for family reasons, effective immediately. Rob von der Porten, Chairman of the Board, has been named interim Executive Chair. Mr. Spearn will also be retiring from the Board at or prior to the next AGM. The Board will commence a search for suitable candidates to take on the CEO position.
MedX Health Signs Exclusive Distribution Agreement to Launch SIAscopy on DermSecure(TM) in Mexico
MedX Health Corp. ("MedX") (TSX-V: MDX) announces that it has signed an Exclusive Distribution Agreement with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico ("MedX Mexico"), which plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX's SIAscopy on DermSecure(TM) Telemedicine platform. The exclusivity was granted to MedX Mexico based on its strong connections within the Mexican marketplace as well as its upfront commitment to cover the application for regulatory approval in Mexico and all marketing costs, and the large-scale distribution network it has secured. The agreement also has a robust performance clause that reflects the strong commitment by MedX Mexico and the opportunity in the Mexican market.
MedX Health Corp. Announces 2019 Year End Results
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announced its results for the year ended December 31, 2019, which are also available on SEDAR (www.sedar.com).
MedX announces issuance of shares in connection with Advertising Services Agreement
MedX Health Corp. ("MedX") (TSX-V: MDX) announces that pursuant to the agreement for an online marketing and awareness program through AGORACOM, that was announced in the Press Release dated June 1, 2020, it has settled the first payment to AGORACOM, in the amount of 12,000 plus HST, or $13,560, by issuance on June 1, 2020, of 90,400 shares at an issue price of $0.15 per share. The issue price of the shares was determined by using the closing price of the Shares of the Company on the TSX Venture Exchange on May 29, 2020, being the last trading day before the date of issuance. The shares were issued pursuant to the prospectus exemption contained in section 2.24 of National Instrument 45-106 Prospectus Exemptions, and are not subject to trading restrictions pursuant to the provisions of National Instrument 45-102, Resale of Securities since the criteria contained in NI 45-102 2.6(3) are met.
MedX Launches AGORACOM Online Marketing and Awareness Program
MedX Health Corp. ("MedX") (TSX-V: MDX) is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM.
MedX Health Corp. Appoints Nick Hoffman, Medical Imaging and Equipment Executive, as Director Business Development
MedX Health Corp. ("MedX") (TSX-V: MDX) is pleased to announce the appointment of medical equipment industry executive Nick Hoffman as Director, Business Development, effective immediately. Mr. Hoffman will be working with the MedX team in managing customer acquisition and support initiatives as the Company commercializes and begins an aggressive installation phase for its SIAscopy on DermSecure(TM) telemedicine platform.
MedX Health Corp. provides update on the release of its Annual Financial Statements and related Disclosures for fiscal 2019 and postponement of release of its First Quarter 2020 Interim Financial Statements and related Disclosures
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announces an update on the filing of its Annual Financial Statements and related Disclosures (the "Annual Disclosures") for the year ended December 31, 2019, following the earlier announcement in its Press Release dated April 28, 2020, that filing of the Annual Disclosures would be delayed due to COVID-19 related delays. The Company is continuing to work diligently and expeditiously with its auditors, and anticipates that the Annual Disclosures will be filed by June 12, 2020, as previously indicated.
MedX Health Corp. Appoints Veteran Healthcare Industry Executive Damon Goodwin as Global Director of Sales
MedX Health Corp. ("MedX") (TSX-V: MDX) is pleased to announce the appointment of healthcare industry executive Damon Goodwin as Global Director of Sales, effective immediately. Mr. Goodwin will play an integral part in MedX's revenue growth by building global partnerships for MedX's skin assessment telemedicine technology. Initially supporting the roll out and expansions in Mexico, Brazil and the USA, he will also be responsible for securing joint ventures & partnerships around the world.
MedX Health Corp. Confirms Details of Closings of Non-Brokered Private Placements
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) confirms the precise specifics of the series of closings of non-brokered private placements made since January 30, 2020, announced in recent Press Releases by the Company. The following Table sets out the particulars of the dates of each closing, the number of units issued and the amount raised on each closing, together with details of Agent's Warrants and cash commissions paid to Agents at each closing.